Final Operational Milestone #3

Over the last year, we completed all the relevant IND enabling studies as well as the IND modules (Clinical protocol, Clinical protocol synopsis, Informed consent, and Investigator’s brochure) documents and submitted the IND to the FDA on September 5th 2019. We are working on preparing for the phase I clinical study (9 patients) that will be taking place at Stanford University.